The Walgreens Boots Alliance NOligarchy Profile
C
O
N
C
E
R
N
I
N
G
Walgreens Boots Alliance scores 38.21 out of 100 on the NOligarchy index — a number that reflects a company spending on political access, handing enormous sums to shareholders while its workforce earns poverty-adjacent wages, and accumulating more than half a billion dollars in legal penalties over just two years. The closer a score sits to zero, the more a company concentrates wealth, bends rules, and insulates itself from accountability. Walgreens sits well below the industry average.
Current Pillar Scores
Political Access
43.2
Wealth Extraction
53.8
Playing by the Rules
1.3
Score history — 23 quarters
Tier bands show where each quarter's score falls — no numeric y-axis needed. The dashed ring marks the year-over-year comparison point. Tap any quarter but the first to see its pillar breakdown.
•
Political Access Grade: 43.22/100. From Q3 2024 through Q2 2026 (8 quarters — the two-year tracking period), Walgreens deployed lobbyists on Capitol Hill, channeled six figures through its Political Action Committee (PAC), and retained an outside lobbying firm with ties across the retail world. The score reflects a sustained effort to maintain access to the lawmakers who set the rules on drug pricing, Medicare reimbursement, and pharmacy regulation.
•
Wealth Extraction Grade: 53.15/100. The company paid its chief executive more than 400 times the median worker’s take-home pay, poured $1.26 billion in dividends into shareholders’ pockets, and repurchased its own stock — all while the people stocking shelves and dispensing prescriptions took home roughly $33,000 a year.
•
Playing by the Rules Grade: 0.8/100. The most damning number in this profile. Walgreens accumulated more than $514 million in penalties from regulators and courts over the two-year period, spanning opioid violations, Medicare fraud, and consumer protection failures. It ranks first — the worst — out of 5 companies in the Health and personal care retailers sector for total fines.
The Sector Context: Walgreens Boots Alliance ranks 4th out of 5 among companies sharing its federal industry classification (Health and personal care retailers) on the overall NOligarchy score. With a sector average of 42.7, Walgreens trails behind the industry baseline — a company of its dominance and reach is, by this measure, one of the least accountable players in its own field. For higher-scoring options in this space, see the Better Alternatives section below.
The Bottom Line: A $148 Billion Company That Pays Fines Faster Than It Raises Wages
Walgreens Boots Alliance pulled in $147.7 billion in annual revenue — enough to make it one of the largest companies in the United States by sales — yet its median worker earned just $32,958 last year, which is less than what it costs to rent a one-bedroom apartment in most major American cities. While regulators were levying more than $514 million in fines for opioid violations and Medicare fraud, the company was simultaneously paying out $1.26 billion in dividends to its wealthiest shareholders and handing its chief executive compensation worth more than 400 times the median worker’s annual paycheck. The most severe imbalance in this profile is not the lobbying spend or even the CEO pay gap — it is a company that treats regulatory penalties as a routine cost of doing business while leaving its 313,941 employees earning wages that qualify many of them for the very government assistance programs Walgreens is simultaneously billing.
Spending to Keep Washington’s Hands Off the Prescription Counter
Over the two-year tracking period, Walgreens spent $400,000 on federal lobbying — roughly $200,000 a year. To a household, that is a fortune. To a company billing $148 billion annually, it is a rounding error deployed with surgical intent. The company’s lobbyists knocked on doors at the Senate 23 times and the House of Representatives 22 times across the tracked filings, working four distinct issue areas.
The heaviest lobbying traffic ran through two closely related channels: Health Issues (8 filings) and Medicare/Medicaid (8 filings). These are not abstract policy areas for Walgreens — they sit at the direct center of how the company earns its money. Walgreens fills hundreds of millions of prescriptions per year, and the reimbursement rates Medicare and Medicaid pay for those prescriptions determine the company’s profit margin on its core business. Lobbying disclosures cite “issues related to pharmacies, pharmacists, and Medicare reimbursement” repeatedly across multiple quarters. Filings also reference Pharmacy Benefit Managers — the middlemen who negotiate between insurers, pharmacies, and drugmakers and who have the power to cut Walgreens out of networks entirely. The company’s lobbyists also tracked the implementation of the Inflation Reduction Act of 2022 (Public Law 117-169), which reshaped drug pricing rules under Medicare.
The third-most-frequent lobbying track was Taxation/Internal Revenue Code (6 filings). Filings describe “issues related to corporate tax, net operating loss, EBITA/EBIDA” — a direct signal that Walgreens was watching Congress for any moves that could affect its ability to offset taxable income. One filing logged in Q3 2024 addressed “issues related to third party labor law inspections” — a single entry, but one that tells a story: a company with more than 313,000 workers has an obvious interest in shaping how aggressively the government audits labor practices.
Walgreens retained one outside firm — Forbes-Tate, tracked through Senate Lobbying Disclosure Act (LDA) filings — which also lobbies for Shein and Tractor Supply Company. Two of Walgreens’ 12 registered lobbyists came through the revolving door: Jeffrey Strunk previously served as Deputy Floor Director and Floor Assistant to House Speaker John Boehner, and Ebony Majette held staff positions in the offices of Representatives Joseph Morelle and Steny Hoyer. Former congressional staff know which hallways to walk and which staff members to call.
Its PAC, tracked at the Federal Election Commission (FEC), spent $210,000 over the period with a 50.9% Democratic / 49.1% Republican partisan split — a deliberate hedge that prioritizes access over ideology.
Walgreens Boots Alliance's PAC gave $82,500 to Democrats and $79,500 to Republicans — a 50.9% / 49.1% split that buys access to whichever party wins.
50.9%
49.1%
Democrats · $82,500
Republicans · $79,500
ACCESS-BUYER PENALTY APPLIED
Individual contributions from company executives added another $18,239 on top, tracked through FEC records.
Shared Lobbying Exposure
Walgreens Boots Alliance
client
FORBES-TATE
lobbying firm
Shein
also a client
Tractor Supply Company
also a client
Why it matters: the same firm argues Walgreens Boots Alliance’s case and its rivals’ — one hire buys a web of shared access that can’t be seen from outside. This network worsens Walgreens Boots Alliance’s political-access score (see methodology for the exact factor).
Over a Billion Dollars to Shareholders, $33,000 to the People Dispensing the Pills
The pay gap at Walgreens is not subtle. The CEO pay ratio is 410:1, according to the company’s own SEC DEF 14A filing. The CEO’s total compensation in the most recent reported fiscal year was about $13.5 million. The median Walgreens employee — most likely a pharmacy technician, a store associate, or a shift supervisor — earned $32,958. That means the chief executive made more before lunchtime on January 2nd than most Walgreens workers earned in the entire year.
Walgreens did not simply neglect its workforce while lavishing cash on executives. It simultaneously chose to funnel over a billion dollars toward its wealthiest shareholders through dividends. Over the period captured in the company’s financial filings, it paid out $1.26 billion in dividends in fiscal 2024. These are not emergency payouts — they are structural, recurring transfers of wealth to the top of the ownership pyramid. The wealthiest 10% of Americans own 93% of all stocks, so the overwhelming majority of those funds flows to people who are not stocking shelves at 6 a.m.
Walgreens also spent $69 million on stock buybacks in fiscal 2024 — a deliberate reduction in shares outstanding that inflates per-share metrics and triggers executive performance bonuses. The company made a deliberate choice. The money spent on buying back its own stock could have instead handed every single one of its 313,941 workers a $219.79 raise, spread across the last 1 fiscal year.
EARNINGS STATEMENT — ANNUAL
EMPLOYEE: 1 of 313,941
Your share of the buyback
+$219.79
Per biweekly paycheck
+$4.23
SPENT INFLATING THE SHARE PRICE
Stock buybacks over the two most recent fiscal years: $69 million.
Spread across Walgreens Boots Alliance's 313,941 employees, its stock buybacks over the last two fiscal years come to $219.79 per worker — about $4 on each of the 52 biweekly paychecks in that span.
Buybacks vs. Workers
What the buyback spend could have meant for 314K employees
Spent on buybacks
$69.0M
directed to shareholders
÷ 314K
workers
Per-worker raise
$220
per employee, 1-year total
Spread over that year, that's a 1% annual raise on the median worker's $32,958 salary — money the company chose to send to shareholders instead.
The dividend picture makes the choice even starker. Walgreens did not abandon dividends in favor of buybacks — it ran both simultaneously. It paid out $1.26 billion to shareholders in fiscal 2024 while also repurchasing $69 million in stock. That is not a company in distress unable to afford better earnings for its workforce. That is a company that chose, quarter after quarter, to reward capital while leaving labor behind.
Buybacks also serve a direct purpose at the executive suite level: when shares outstanding shrink, Earnings Per Share (EPS) rises automatically, even when actual profits are flat. That mechanical bump directly triggers the performance-based compensation targets written into executive bonus agreements — the same executives who approved the buyback programs in the first place. With a 410:1 pay ratio already in place, that feedback loop compounds existing inequality.
$514 Million in Penalties While the Opioid Crisis Burned
Walgreens accumulated $514.4 million in total penalties across 12 cases over the two-year tracking period from Q3 2024 through Q2 2026 — more than any other company in the Health and personal care retailers sector. That is not a series of isolated stumbles. It is a pattern.
The single largest category, by a wide margin, was Controlled Substances Act violations — $300 million in a single case settled with the Department of Justice (DOJ) in 2025. To put that number in human terms: $300 million is more than 9,000 times what a median Walgreens employee earns in a year. That settlement reflects findings that Walgreens pharmacies dispensed controlled substances in ways that violated federal law — directly relevant to a company that positioned itself as a trusted neighborhood health provider during the worst drug overdose crisis in American history.
False Claims Act violations — meaning allegations that Walgreens billed federal health programs for things it should not have — account for another $207.4 million across three cases. The largest was a $106.8 million DOJ Civil settlement in 2024, followed by a $97.8 million multi-agency resolution in 2025, and a $2.8 million U.S. Attorney’s Office action also in 2025. These are not billing errors. The False Claims Act specifically covers fraud against Medicare and Medicaid — the same federal programs its lobbyists were simultaneously filing on.
Regulatory Violations by Year
$514.4M · 10 cases
$107.3M
2024
2 cases
$401.1M
2025
6 cases
$6.0M
2026
2 cases
Consumer protection violations added $6.5 million across three cases, including a $6 million California multi-agency action in 2026 and a $500,000 Vermont Attorney General settlement in 2025. Rounding out the record: a wage and hour violation costing $460,000, an air pollution infraction in 2026 ($32,149), two workplace safety citations ($23,596 combined), and a drug or medical equipment safety finding ($15,000).
The breadth of this record matters as much as the dollar total. Walgreens was penalized across seven distinct offense categories in two years — from how it handled controlled substances to how it treated its own workers to whether the air around its facilities was clean. No single regulator caught this; it took the DOJ, state attorneys general, federal workplace agencies, and environmental enforcers working independently to accumulate this ledger. This two-year window is a fraction of the company’s full docket visible on the source site.
At $147.7 billion in annual revenue, a $514.4 million penalty bill equals roughly 0.35% of yearly sales. That is the math that makes fines a manageable line item rather than a deterrent — small enough to absorb, large enough to headline, never large enough to change the underlying behavior.
While regulators were extracting hundreds of millions in fines, governments were separately handing Walgreens public money. Across 2024–2025, the company received $129,062 in public subsidies across two grants — including $64,682 in 2024. Against $514.4 million in penalties, the subsidy figure is a footnote. But it marks the same two years in which the public simultaneously penalized Walgreens for breaking the rules and subsidized it for showing up.